The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. - Concepedia

Concepedia

Publication | Closed Access

The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.

90

Citations

32

References

2002

Year

Shiuw H. Han, John M. H. de Klerk, Suzy Tan, Alfred D. van het Schip, Bert H. Derksen, Aalt van Dijk, Cas Kruitwagen, Geert H. Blijham, Peter P. van Rijk, Bernard A. Zonnenberg

Abstract

This randomized controlled trial confirmed that, compared with placebo, (186)Re-etidronate resulted in a significantly longer pain response in the treatment of bone pain from metastasized prostate cancer.

References

	Year	Citations

Page 1